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Abstract 
Background: As a sub-analysis of the PROLOGUE study, we evaluated the long-term effect of sitagliptin, a dipeptidyl 
peptidase 4 inhibitor, on endothelial function in the conduit brachial artery in patients with type 2 diabetes.
Methods: In the PROLOGUE study, patients were randomly assigned to either add-on sitagliptin treatment (sitaglip-
tin group) or continued conventional antihyperglycemic treatment (conventional group). Among the 463 participants 
in the PROLOGUE study, FMD was measured in 17 patients in the sitagliptin group and 18 patients in the conventional 
group at the beginning and after 12 and 24 months of treatment.
Results: HbA1c levels were significantly decreased after 12 and 24 months of treatment compared to baseline values 
in both groups (7.0 ± 0.4 vs. 6.6 ± 0.3 and 6.6 ± 0.4 % in the sitagliptin group; 7.0 ± 0.6 vs. 6.6 ± 0.7 and 6.6 ± 0.7 % 
in the conventional group; P < 0.05, respectively). There was no significant difference between FMD values at base-
line and after 12 and 24 months in the sitagliptin group (4.3 ± 2.6 vs. 4.4 ± 2.1 and 4.4 ± 2.3 %, P = 1.0, respectively). 
Although FMD had a tendency to increase from 4.3 ± 2.4 % at baseline to 5.2 ± 1.9 % after 12 months and 5.1 ± 2.2 % 
after 24 months in the conventional group, there was no significant difference between FMD values at baseline and 
after 12 and 24 months (P = 0.36 and 0.33, respectively).
Conclusions: Add-on sitagliptin to conventional antihyperglycemic drugs in patients with type 2 diabetes did not 
alter endothelial function in the conduit brachial artery measured by FMD during a 2-year study period. Sitagliptin 
may be used without concern for an adverse effect on endothelial function in patients with type 2 diabetes.
Trial registration: University hospital Medical Information Network (UMIN) Center: ID UMIN000004490
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Background
Endothelial dysfunction is the initial step in the patho-
genesis of atherosclerosis and plays an important role 
in the development of this condition [1, 2]. In addi-
tion, it has been shown that endothelial function is an 
independent predictor of cardiovascular events [3]. Type 
2 diabetes, an important risk factor for cardiovascular 
disease, is associated with endothelial dysfunction [4, 5]. 
Several investigators have reported that lifestyle modifi-
cation and pharmacological therapy, including antihyper-
glycemic agents, improve endothelial function in patients 
with type 2 diabetes [6–9]. These findings suggest that 
endothelial dysfunction is reversible and can be restored 
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An orally administered dipeptidyl peptidase 4 (DPP-4) 
inhibitor is now available for treatment of type 2 diabe-
tes. The DPP-4 inhibitor prolongs the action of incretin 
hormones by inhibition of their breakdown and improves 
glycemic control through incretin hormone-induced 
decrease in glucagon levels and increase in endogenous 
insulin secretion in patients with type 2 diabetes. The 
relationship between treatment with a DPP-4 inhibitor 
and endothelial function in patients with type 2 diabetes 
has been evaluated [10–13]. Sitagliptin, a DPP-4 inhibitor, 
has been demonstrated to significantly improve microvas-
cular endothelial function assessed by the reactive hyper-
emia peripheral arterial tonometry index after 6 months 
in uncontrolled diabetic patients with coronary heart dis-
ease [10]. As for the relationship between a DPP-4 inhibi-
tor and endothelial function in the conduit brachial artery 
assessed by flow-mediated vasodilation (FMD), a previous 
short-term study demonstrated that 6-week treatment 
with DPP-4 inhibitors, including sitagliptin and aloglip-
tin, attenuated FMD [11], whereas other previous stud-
ies demonstrated that 12-week treatment with sitagliptin 
improved FMD in patients with type 2 diabetes [12, 13]. 
However, the long-term effect of a DPP-4 inhibitor on 
FMD in patients with type 2 diabetes remains unclear.
The PROLOGUE study was a prospective multicenter 
study conducted to evaluate the inhibitory effect of a 
DPP-4 inhibitor on progression of atherosclerosis based 
on carotid artery intima-media thickness (IMT) assessed 
by ultrasonography over a 2-year follow-up period [14]. 
In that study, FMD in the brachial artery was also meas-
ured in some of the subjects. Therefore, we carried out 
the present study as a sub-analysis of the PROLOGUE 
study to evaluate the long-term effect of a DPP-4 inhibi-
tor on endothelial function assessed by FMD in the bra-
chial artery in patients with type 2 diabetes.
Methods
Study design and patients
The rationale and design of the PROLOGUE study (Uni-
versity Hospital Medical Information Network Center: 
ID 000004490) have been described previously [15]. In 
brief, the PROLOGUE study was a multicenter, prospec-
tive, randomized, open-label trial and blinded-endpoint 
trial carried out with the participation of 48 Japanese 
institutions. Eligible patients were at least 30 years of age 
and who had type 2 diabetes with HbA1c level of 6.2–
9.4 % despite conventional treatment with diet, exercise 
and/or pharmacologic therapy with oral antihypergly-
cemic agents (except incretin-related therapy) for more 
than 3 months. Patients who had taken a DPP-4 inhibi-
tor, glucagon-like peptide-1 (GLP-1) analogs, or insulin 
before randomization were excluded. Other exclusion 
criteria are described elsewhere [15].
Between June 2011 and September 2012, a total of 463 
patients with type 2 diabetes were enrolled and randomly 
assigned in a 1:1 ratio to either add-on sitagliptin treat-
ment (sitagliptin group: n  =  232) or conventional anti-
hyperglycemic treatment (conventional group: n = 231). 
The treatment randomization was conducted on basis 
of the age, gender, use of statins, pre-treatment diabetic 
type (non-pharmacological or pharmacological treat-
ment), HbA1c (<7 or  ≥7  %), office systolic blood pres-
sure (<135 or ≥135  mm  Hg), and maximum IMT (<1.0 
or ≥1.0 mm) [15]. All patients were treated with the aim 
of achieving a targeted HbA1c level less than 6.2  % or 
fasting plasma glucose level less than 110 mg/dL during 
the study period. Treatment of patients in the sitagliptin 
group was initially started with sitagliptin at a dose of 
50 mg daily. If further glycemic intervention was neces-
sary, the dose of sitagliptin was increased up to 100 mg 
daily within 3 months, and conventional antihyperglyce-
mic agents other than DPP-4 inhibitors, GLP-1 analogs 
and/or insulin were added. If further glycemic interven-
tion was necessary in patients in the conventional group, 
antihyperglycemic agents other than DPP-4 inhibitors, 
GLP-1 analogs and/or insulin were added. All of the 
patients were followed up annually for 2 years until Sep-
tember 2014.
In the PROLOGUE study, the primary endpoint was 
the change in mean common carotid artery-IMT at 
24 months after treatment. Carotid ultrasound examina-
tions were performed at the beginning of treatment and 
after 12 and 24 months of treatment. The secondary out-
comes included changes in FMD in the brachial artery 
after 12 and 24 months of treatment [15]. In some of the 
participating institutions, FMD in the brachial artery was 
also measured as an optional examination. Of a total of 
463 patients, serial measurement of FMD was performed 
in 17 patients in the sitagliptin group and 18 patients in 
the conventional group at the beginning and after 12 and 
24  months of treatment. The data for these 35 patients 
from 4 institutions were analyzed in the present study. 
This sub-study is a pre-specified analysis. The ethical 
committees of the participating institutions approved the 
study protocol. Written informed consent for participa-
tion in the study was obtained from all subjects.
Study protocol
All studies were performed in the morning, after over-
night fasting, in a quiet, dark, and air-conditioned 
room (constant temperature of 22–25  °C). The sub-
jects were kept in the supine position throughout the 
study. A 23-gauge polyethylene catheter was inserted 
into the left deep antecubital vein to obtain blood sam-
ples. The vascular response to reactive hyperemia in 
the brachial artery was used for the assessment of 
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endothelium-dependent FMD. The observers were blind 
to the form of examination.
Measurement of FMD
The same protocol for measurement of FMD in the bra-
chial artery was used in the study. FMD was measured 
using the same ultrasound instrument specialized for 
FMD measurements in all institutions. A high-resolu-
tion linear artery transducer was coupled to computer-
assisted analysis software (UNEXEF18G, UNEX Co, 
Nagoya, Japan) that used an automated edge detection 
system for measurement of brachial artery diameter. 
A blood pressure cuff was placed around the forearm. 
The brachial artery was scanned longitudinally 5–10 cm 
above the elbow. When the clearest B-mode image of 
the anterior and posterior intimal interfaces between the 
lumen and vessel wall was obtained, the transducer was 
held at the same point throughout the scan by a special 
probe holder (UNEX Co) to ensure consistency of the 
image. Depth and gain setting were set to optimize the 
images of the arterial lumen wall interface. When the 
tracking gate was placed on the intima, the artery diam-
eter was automatically tracked, and the waveform of 
diameter changes over the cardiac cycle was displayed 
in real time using the FMD mode of the tracking system. 
This allowed the ultrasound images to be optimized at 
the start of the scan and the transducer position to be 
adjusted immediately for optimal tracking performance 
throughout the scan. Pulsed Doppler flow was assessed 
at baseline and during peak hyperemic flow, which was 
confirmed to occur within 15 s after cuff deflation. Blood 
flow velocity was calculated from the color Doppler data 
and was displayed as a waveform in real time. The base-
line longitudinal image of the artery was acquired for 
30  s, and then the blood pressure cuff was inflated to 
50 mm Hg above systolic pressure for 5 min. The longitu-
dinal image of the artery was recorded continuously until 
5 min after cuff deflation. Pulsed Doppler velocity signals 
were obtained for 20 s at baseline and for 10 s immedi-
ately after cuff deflation. Changes in brachial artery diam-
eter were immediately expressed as percentage change 
relative to the vessel diameter before cuff inflation. FMD 
was automatically calculated as the percentage change in 
peak vessel diameter from the baseline value. Percent-
age of FMD [(Peak diameter − Baseline diameter)/Base-
line diameter] was used for analysis. Blood flow volume 
was calculated by multiplying the Doppler flow velocity 
(corrected for the angle) by heart rate and vessel cross-
sectional area (−r2). Reactive hyperemia was calculated 
as the maximum percentage increase in flow after cuff 
deflation compared with baseline flow. Inter- and intra-
coefficients of variation for the brachial artery diameter 
were 1.6 and 1.4 %, respectively.
Statistical analysis
Results are presented as mean ± SD. All reported proba-
bility values were 2-sided, and a probability value of <0.05 
was considered statistically significant. Categorical vari-
ables were compared by means of the Chi square test. We 
compared mean values of continuous variables between 
the 2 groups by unpaired Student’s t test. Differences in 
mean values of continuous variables between baseline, 12 
and 24 months were compared by paired Student’s t test 
with Bonferroni’s correction. The data were processed 
using the software package Stata version 9 (Stata Co., 
College Station, Texas, USA).
Results
Baseline clinical characteristics
Table  1 shows the baseline clinical characteristics of all 
patients and the effects of each treatment on baseline 
parameters in the sitagliptin group and conventional 
group. Of the 35 patients, 20 (57.1 %) were men and 15 
(42.9 %) were women. Twenty-six (74.3 %) had hyperten-
sion, 25 (71.4 %) had dyslipidemia, 5 (19.2 %) were cur-
rent smokers, 18 (51.4 %) had coronary heart disease, and 
3 (8.5 %) had cerebrovascular disease. The mean fasting 
plasma glucose level was 7.04  ±  1.11  mmol/L and the 
mean HbA1c level was 7.0 ±  0.5  %. The mean value of 
FMD was 4.3 ± 2.4 %. There was no significant difference 
in any of the variables except the prevalence of current 
smokers between the two groups. Although serum levels 
of creatinine and lipids did not significantly change dur-
ing the treatment period, systolic blood pressure was sig-
nificantly higher after 24 months in the sitagliptin group 
than in the conventional group.
Glycemic control
HbA1c and fasting plasma glucose levels were similar at 
baseline between the two groups. HbA1c levels were sig-
nificantly decreased after 12 and 24 months of treatment 
compared to baseline values in both groups (7.0  ±  0.4 
vs. 6.6  ±  0.3 and 6.6  ±  0.4  % in the sitagliptin group; 
7.0 ± 0.6 vs. 6.6 ± 0.7 and 6.6 ± 0.7 % in the conventional 
group; P < 0.05, respectively, Fig. 1a). No significant dif-
ference in fasting plasma glucose level was observed dur-
ing the study period in either group (Fig. 1b).
Endothelial function
Effects of glycemic intervention on FMD at baseline 
and after 12 and 24 months of treatment in the sitaglip-
tin group and conventional group are shown in Fig.  2. 
FMD values were similar at baseline in the two groups. 
There was no significant difference between FMD values 
at baseline and after 12 and 24 months in the sitagliptin 
group (4.3 ± 2.6 vs. 4.4 ± 2.1 and 4.4 ± 2.3 %, P = 1.0, 
respectively). Although FMD rose from 4.3  ±  2.4  % at 
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Table 1 Clinical characteristics of the subjects
HDL high-density lipoprotein; ARB angiotensin receptor blockers; ACE angiotensin converting enzyme
* P < 0.05 vs. control group
Variables All (n = 35) Conventional group (n = 18) Sitagliptin group (n = 17)
0 month 0 month 12 months 24 months 0 month 12 months 24 months
Age, y 66.5 ± 8.9 64.1 ± 10.3 69.1 ± 6.5
Male, n (%) 20 (57.1) 11 (61.1) 9 (52.9)
Body mass index, kg/m2 27.0 ± 4.2 27.2 ± 5.0 27.1 ± 4.9 27.0 ± 4.8 26.8 ± 3.3 26.9 ± 3.3 26.5 ± 3.0
Systolic blood pressure, 
mm Hg
128.0 ± 13.1 127.2 ± 14.0 129.5 ± 15.3 123.6 ± 12.5 136.9 ± 16.7 138.6 ± 15.6 133.2 ± 13.3*
Diastolic blood pressure, 
mm Hg
72.8 ± 10.1 78.8 ± 10.6 75.4 ± 10.9 72.4 ± 10.2 79.8 ± 8.9 78.5 ± 8.8 76.5 ± 8.8
Heart rate, bpm 67.3 ± 9.5 67.1 ± 8.6 67.7 ± 10.3 67.9 ± 8.5 67.2 ± 9.6 65.6 ± 10.7 68.0 ± 12.9
Creatinine, μmol/L 72.0 ± 19.5 71.8 ± 19.3 70.5 ± 19.6 79.5 ± 24.6 72.2 ± 20.2 72.2 ± 22.7 76.8 ± 24.3
Total cholesterol, mmol/L 4.66 ± 0.75 4.74 ± 0.87 4.95 ± 1.19 4.72 ± 0.98 4.57 ± 0.60 4.57 ± 0.78 4.60 ± 0.69
Triglycerides, mmol/L 1.38 ± 0.48 1.49 ± 0.47 1.55 ± 0.53 1.19 ± 0.31 1.26 ± 0.47 1.26 ± 0.65 1.43 ± 0.97
HDL cholesterol, mmol/L 1.42 ± 0.37 1.38 ± 0.45 1.44 ± 0.40 1.45 ± 0.37 1.47 ± 0.27 1.46 ± 0.33 1.47 ± 0.34
Glucose, mmol/L 7.04 ± 1.11 7.03 ± 1.04 7.14 ± 1.46 6.66 ± 1.67 7.05 ± 1.21 6.66 ± 1.27 6.48 ± 0.81
HbA1c, % 7.0 ± 0.5 7.0 ± 0.6 6.6 ± 0.7 6.6 ± 0.7 7.0 ± 0.4 6.6 ± 0.3 6.6 ± 0.4
Brachial artery diameter, 
mm
4.08 ± 0.55 4.05 ± 0.60 4.02 ± 0.60 3.98 ± 0.58 4.11 ± 0.52 4.14 ± 0.59 4.19 ± 0.67
Current smoker, n (%) 5 (19.2) 5 (41.7) 0 (0)*
Complications
Hypertension, n (%) 26 (74.3) 13 (72.2) 13 (76.5)
Dyslipidemia, n (%) 25 (71.4) 11 (61.1) 14 (82.4)
Coronary heart disease, 
n (%)
18 (51.4) 8 (44.4) 10 (58.8)
Cerebrovascular disease, 
n (%)
3 (8.5) 2 (11.1) 1 (5.9)
Antidiabetic drugs
Sulfonylurea, n (%) 10 (28.6) 5 (27.8) 6 (33.0) 6 (33.0) 5 (29.4) 3 (17.6) 3 (17.6)
Metformin, n (%) 9 (25.7) 5 (27.8) 7 (38.9) 7 (38.9) 4 (23.5) 5 (29.4) 5 (29.4)
α-Glucosidase inhibitor, 
n (%)
13 (37.1) 4 (22.2) 8 (44.4) 8 (44.4) 9 (52.9) 6 (35.3) 6 (35.3)
Pioglitazone, n (%) 4 (11.4) 2 (11.1) 3 (16.7) 3 (16.7) 2 (11.8) 1 (5.9) 1 (5.9)
Glinide, n (%) 1 (2.9) 0 (0) 1 (5.6) 1 (5.6) 1 (5.9) 0 (0) 0 (0)
Antihyperlipidemic drugs
Statin, n (%) 21 (60.0) 8 (44.4) 8 (44.4) 9 (50.0) 13 (76.4) 12 (70.1) 12 (70.1)
Fibrate, n (%) 2 (5.7) 2 (11.1) 2 (11.1) 2 (11.1) 0 (0) 0 (0) 0 (0)
Eicosapentaenoic acid, n (%) 2 (5.7) 1 (5.6) 1 (5.6) 1 (5.6) 1 (5.9) 1 (5.9) 1 (5.9)
Ezetimibe, n (%) 1 (2.9) 0 (0) 0 (0) 0 (0) 1 (5.9) 1 (5.9) 1 (5.9)
Antihypertensive drugs
Calcium channel blocker, 
n (%)
21 (60.0) 11 (61.1) 11 (61.1) 11 (61.1) 10 (58.8) 10 (58.8) 10 (58.8)
ARB, n (%) 20 (57.1) 11 (61.1) 11 (61.1) 11 (61.1) 9 (52.9) 10 (58.8) 10 (58.8)
ACE inhibitor, n (%) 5 (14.2) 3 (16.7) 3 (16.7) 3 (16.7) 2 (11.8) 1 (5.9) 1 (5.9)
Diuretic, n (%) 8 (22.9) 3 (16.7) 3 (16.7) 4 (22.2) 5 (29.4) 5 (29.4) 5 (29.4)
Beta-blocker, n (%) 8 (22.9) 4 (22.2) 4 (22.2) 4 (22.2) 4 (23.5) 5 (29.4) 5 (29.4)
Others
Antiplatelet agent, n (%) 18 (51.4) 7 (38.9) 7 (38.9) 7 (38.9) 11 (64.7) 12 (70.6) 12 (70.6)
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baseline to 5.2 ± 1.9 % after 12 months and 5.1 ± 2.2 % 
after 24 months in the conventional group, there was no 
significant difference between FMD values at baseline 
and after 12 and 24 months (P = 0.36 and 0.33, respec-
tively). There was no significant difference between the 
two groups in FMD after 12 and 24 months (P = 0.22 and 
0.31, respectively).
Discussion
In the present study, similar degrees of improvement in 
glycemic control were achieved in the sitagliptin group 
and the conventional group. The present study demon-
strated that the addition of sitagliptin to usual care in 
patients with type 2 diabetes did not alter endothelial 
function assessed by FMD in the conduit brachial artery 
over a 2-year study period.
In the present study, patients who had taken a DPP-4 
inhibitor, GLP-1 analogs, or insulin before randomiza-
tion were excluded. Moreover, additional use of incretin-
related antihyperglycemic agents and insulin for further 
glycemic intervention was inhibited in the conventional 
group during the study period according to the study 
protocol. Therefore, the control treatment did not mask 
any true effect of sitagliptin in this study.
Short-term effects of treatment with sitagliptin on 
FMD have been controversially reported [11–13]. Ayaori 
et  al. [11] demonstrated that 6-week sitagliptin therapy 
significantly attenuated FMD despite improved diabetic 
status, whereas two other previous studies demonstrated 
that 12-week sitagliptin therapy significantly improved 
FMD [12, 13], suggesting that at least 12 weeks of treat-



























































Fig. 1 Line graphs show hemoglobin A1c level (a) and fasting glucose level (b) at each study visit in the sitagliptin group and conventional group
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endothelial function. However, the long-term effect of 
sitagliptin therapy on FMD has remained unclear. In 
the present study, we demonstrated that FMD was not 
altered after 12 and 24 months. FMD was maintained at 
a similar level during the study period by treatment with 
sitagliptin in patients with type 2 diabetes. Recently, a 
cardiovascular safety concern regarding the long-term 
use of some antihyperglycemic agents has been raised 
[16, 17]. Therefore, new antihyperglycemic agents are 
required not only to show glucose-lowering ability but 
also to be not associated with increases in major adverse 
cardiovascular events [18]. A cardiovascular effect of 
sitagliptin has been shown in experimental and clinical 
studies [19, 20]. In an experimental model, it was dem-
onstrated that sitagliptin can reduce the area of athero-
sclerotic lesions, possibly by regulating the AMPK and 
MAPK pathways and then reducing leukocyte-endothe-
lial cell interaction and inflammation reactions [19]. 
Moreover, sitagliptin treatment has neutral effects on 
left ventricular diastolic function in diabetic patients 
[20]. A recent study demonstrated that adding sitaglip-
tin to usual care in patients with both type 2 diabetes and 
established cardiovascular disease did not increase the 
risk of major adverse cardiovascular events or hospitali-
zation for heart failure during a median follow-up period 
of 3.0 years [21]. In the secondary analysis of the study, it 
was demonstrated that sitagliptin does not affect the risk 
of hospitalization for heart failure in patients with type 2 
diabetes, both overall and among high-risk patient sub-
groups [22]. These results are supported by our finding 
that 2-year add-on sitagliptin therapy was not associated 
with impairment of endothelial function in the conduit 
brachial artery assessed by FMD, an independent predic-
tor of cardiovascular events.
In the conventional group, FMD increased, but not sig-
nificantly, from 4.3 ± 2.4 % at baseline to 5.2 ± 1.9 % after 
12  months and 5.1  ±  2.2  % after 24  months. In accord-
ance with the study protocol, the use of antihyperglycemic 
agents other than DPP-4 inhibitors, GLP-1 analogs and/
or insulin was encouraged as required, with the aim of 
achieving the target HbA1c level in the conventional group 
during the study period. Several studies have shown that 
some antihyperglycemic agents have beneficial effects on 
endothelial function. Treatment with metformin, pioglita-
zone, or an α-glucosidase inhibitor in patients with type 
2 diabetes has been demonstrated to improve endothe-
lial function assessed by FMD [13, 23–26]. Patients in the 
conventional group received additional antihyperglycemic 
agents, including metformin, α-glucosidase inhibitor and 
pioglitazone, instead of sitagliptin added in the sitagliptin 
group, to achieve the target HbA1c level. The addition of 
these antihyperglycemic agents might have contributed to 
the increasing tendency in FMD in the conventional group.
Limitations
A major limitation of this study is a small sample size. The 
present study was a sub-analysis of the PROLOGUE study, 
and the number of study subjects was relatively small. 
Unfortunately, there is no sample size for power calcula-
tion since FMD was a voluntary measurement parameter 
in the PROLOGUE trial, and this may be underpowered. 
Further studies enrolling a large number of subjects are 
needed to confirm the long-term effect of a DPP-4 inhibi-


































Fig. 2 Line graphs show flow-mediated vasodilation at each study visit in the sitagliptin group and conventional group
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Conclusions
Adding sitagliptin to usual care in patients with type 2 
diabetes did not alter endothelial function in the con-
duit brachial artery measured by FMD during a 2-year 
study period. Sitagliptin may be used in patients with 
type 2 diabetes without concern for an adverse effect on 
endothelial function (Additional file 1).
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